Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics

References

• SnyderRGlasserDAntibiotic therapy for ocular infectionWest J Med199416165795847856158
   PubMedGoogle Scholar
• HughesLMauriceDA fresh look at iontophoresisArch Ophthalmol198410212182518296508622
   PubMedGoogle Scholar
• HovdingGAcute bacterial conjunctivitisActa Ophthalmol200886151717970823
   PubMed Web of Science ®Google Scholar
• RosePManagement strategies for acute infective conjunctivitis in primary care: a systematic reviewExpert Opin Pharmacother20078121903192117696792
   PubMed Web of Science ®Google Scholar
• AllanBDDartJKStrategies for the management of microbial keratitisBr J Ophthalmol19957987777867547792
   PubMed Web of Science ®Google Scholar
• BourcierTThomasFBorderieVChaumeilCLarocheLBacterial keratitis: predisposing factors, clinical and microbiological review of 300 casesBr J Ophthalmol200387783483812812878
   PubMed Web of Science ®Google Scholar
• GreenMApelAStapletonFRisk factors and causative organisms in microbial keratitisCornea2008271222718245962
   PubMed Web of Science ®Google Scholar
• GreenMDApelAJNaduvilathTStapletonFJClinical outcomes of keratitisClin Experiment Ophthalmol200735542142617651246
   PubMed Web of Science ®Google Scholar
• CalleganMCGilmoreMSGregoryMBacterial endophthalmitis: therapeutic challenges and host-pathogen interactionsProg Retin Eye Res200726218920317236804
   PubMed Web of Science ®Google Scholar
• DeCroosFCAfshariNAPerioperative antibiotics and anti-inflammatory agents in cataract surgeryCurr Opin Ophthalmol2008191222618090893
   PubMed Web of Science ®Google Scholar
• KowalskiRPDhaliwalDKOcular bacterial infections: current and future treatment optionsExpert Rev Anti Infect Ther20053113113915757463
   PubMedGoogle Scholar
• Tovilla-CanalesJLNavaATovilla y PomarJLOrbital and periorbital infectionsCurr Opin Ophthalmol200112533534111588494
   PubMed Web of Science ®Google Scholar
• CampolattaroBNLuederGTTychsenLSpectrum of pediatric dacryocystitis: medical and surgical management of 54 casesJ Pediatr Ophthalmol Strabismus19973431431539168418
   PubMed Web of Science ®Google Scholar
• Summary benchmarks for preferred practice pattern guidelinesSan Francisco, CAAmerican Academy of Ophthalmology2007
   Google Scholar
• American Academy of Ophthalmology Cornea and External Disease PanelPreferred practice pattern: conjunctivitisSan Francisco, CAAmerican Academy of Ophthalmology2003
   Google Scholar
• American Academy of Ophthalmology Cornea and External Disease PanelPreferred practice pattern: bacterial keratitisSan Francisco, CAAmerican Academy of Ophthalmology2005
   Google Scholar
• DartJKRadfordCFMinassianDVermaSStapletonFRisk factors for microbial keratitis with contemporary contact lenses: a case-control studyOphthalmology2008115101647165418597850
   PubMed Web of Science ®Google Scholar
• DonahueSPKhouryJMKowalskiRPCommon ocular infections. A prescriber’s guideDrugs19965245265408891465
   PubMed Web of Science ®Google Scholar
• BartlettJDOphthalmic Drug Facts20th edSt Louis, MOWolters Kluwer Health2009
   Google Scholar
• MulliganMJCobbsCGBacteriostatic versus bactericidal activityInfect Dis Clin North Am1989333893982671128
   PubMedGoogle Scholar
• FraunfelderFCorneal toxicity from topical ocular and systemic medicationsCornea200625101133113817172885
   PubMed Web of Science ®Google Scholar
• SchlechBABlondeauJFuture of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX)Surv Ophthalmol200550Suppl 1S64S6716257312
   PubMed Web of Science ®Google Scholar
• KowalskiRPDhaliwalDKKarenchakLMGatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolatesAm J Ophthalmol2003136350050512967804
   PubMed Web of Science ®Google Scholar
• StrattonCWDead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistanceEmerg Infect Dis200391101612533275
   PubMed Web of Science ®Google Scholar
• AsbellPASahmDFNationwide antimicrobial susceptibility surveillance of ocular isolates: results of Ocular TRUSTPresented at the American Society of Cataract and Refractive Surgery Annual Meeting2007 Apr 22–May 2San Diego, CAAbstract #P-114.
   Google Scholar
• AsbellPAColbyKADengSOcular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolatesAm J Ophthalmol2008145695195818374299
   PubMed Web of Science ®Google Scholar
• AsbellPASahmDFShawMDraghiDCBrownNPIncreasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005J Cataract Refract Surg200834581481818471638
   PubMed Web of Science ®Google Scholar
• HwangDGThe top four errors in prescribing antibioticsCataract Refract Surg Today220055558
   Google Scholar
• BlondeauJMHansenGMetzlerKHedlinPThe role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentrationJ Chemother200416Suppl 311915334827
   PubMedGoogle Scholar
• BartlettJDJaanusSClinical Ocular PharmacologySt. Louis, MOButterworth Heinemann Elsevier2008
   Google Scholar
• CavuotoKZutshiDKarpCLMillerDFeuerWUpdate on bacterial conjunctivitis in South FloridaOphthalmology20081151515617572497
   PubMed Web of Science ®Google Scholar
• SheikhAHurwitzBAntibiotics versus placebo for acute bacterial conjunctivitisCochrane Database Syst Rev20062CD00121116625540
   PubMed Web of Science ®Google Scholar
• PachigollaGBlomquistPCavanaghHDMicrobial keratitis pathogens and antibiotic susceptibilities: a 5-year review of cases at an urban county hospital in north TexasEye Contact Lens2007331454917224678
   PubMedGoogle Scholar
• KeayLEdwardsKNaduvilathTMicrobial keratitis predisposing factors and morbidityOphthalmology2006113110911616360210
   PubMed Web of Science ®Google Scholar
• Ciloxan [package insert]Fort Worth, TXAlcon Laboratories, Inc31998
   Google Scholar
• Ocuflox [package insert]Irvine, CAAllergan Inc71993
   Google Scholar
• Iquix [package insert]Jacksonville, FLVistakon Pharmaceuticals LLC42007
   Google Scholar
• BhavsarARIpMSGlassmanARThe risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trialsAm J Ophthalmol2007144345445617765429
   PubMed Web of Science ®Google Scholar
• JonasJBIntravitreal triamcinolone acetonide: a change in a paradigmOphthalmic Res200638421824516763379
   PubMed Web of Science ®Google Scholar
• TabanMBehrensANewcombRAcute endophthalmitis following cataract surgery: a systematic review of the literatureArch Ophthalmol2005123561362015883279
   PubMedGoogle Scholar
• WestESBehrensAMcDonnellPJTielschJMScheinODThe incidence of endophthalmitis after cataract surgery among the US Medicare population increased between 1994 and 2001Ophthalmology200511281388139415953637
   PubMed Web of Science ®Google Scholar
• JohnsonMDoftBKelseySThe Endophthalmitis Vitrectomy Study: relationship between clinical presentation and microbiologic spectrumOphthalmology199710422612729052630
   PubMed Web of Science ®Google Scholar
• JagerRAielloLPatelSCunninghamEJRisks of intravitreous injection: a comprehensive reviewRetina200424567669815492621
   PubMed Web of Science ®Google Scholar
• JonasJBKreissigISpandauUHHarderBInfectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonideAm J Ophthalmol2006141357958016490517
   PubMed Web of Science ®Google Scholar
• JonasJBSpandauUHRenschFVon BaltzSSchlichtenbredeFInfectious and noninfectious endophthalmitis after intravitreal bevacizumabJ Ocul Pharmacol Ther200723324024217593007
   PubMed Web of Science ®Google Scholar
• JonasJBSpandauUHSchlichtenbredeFShort-term complications of intravitreal injections of triamcinolone and bevacizumabEye200822459059118292795
   PubMed Web of Science ®Google Scholar
• YamJCKwokAKUpdate of the management of postoperative endophthalmitisHong Kong Med J200410533734315479963
   PubMedGoogle Scholar
• ChhabraSKunimotoDYKaziLEndophthalmitis after open globe injury: microbiologic spectrum and susceptibilities of isolatesAm J Ophthalmol2006142585285417056367
   PubMed Web of Science ®Google Scholar
• RecchiaFMBusbeeBGPearlmanRBCarvalho-RecchiaCAHoACChanging trends in the microbiologic aspects of postcataract endophthalmitisArch Ophthalmol2005123334134615767476
   PubMedGoogle Scholar
• MoshirfarMFeizVVitaleATWegelinJABasavanthappaSWolseyDHEndophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case seriesOphthalmology2007114468669117184840
   PubMed Web of Science ®Google Scholar
• OlsonRReducing the risk of postoperative endophthalmitisSurv Ophthalmol200449Suppl 2S55S6115028480
   PubMed Web of Science ®Google Scholar
• KelkarAKelkarJAmuakuWKelkarUShaikhAHow to prevent endophthalmitis in cataract surgeriesIndian J Ophthalmol200856540340718711270
   PubMed Web of Science ®Google Scholar
• Endophthalmitis Study GroupEuropean Society of Cataract and Refractive SurgeonsProphylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factorsJ Cataract Refract Surg200733697898817531690
   PubMed Web of Science ®Google Scholar
• MasketSPreventing, diagnosing, and treating endophthalmitisJ Cataract Refract Surg19982467257269642575
   PubMed Web of Science ®Google Scholar
• SchmitzSDickHKrummenauerFPfeifferNEndophthalmitis in cataract surgery: results of a German surveyOphthalmology1999106101869187710519579
   PubMed Web of Science ®Google Scholar
• JacksonWBlepharitis: current strategies for diagnosis and managementCan J Ophthalmol200843217017918347619
   PubMed Web of Science ®Google Scholar
• GrodenLMurphyBRodniteJLid flora in blepharitisCornea19911050532019106
   PubMed Web of Science ®Google Scholar
• RutarTZwickOMCockerhamKPHortonJCBilateral blindness from orbital cellulitis caused by community-acquired methicillin-resistant Staphylococcus aureusAm J Ophthalmol2005140474074216226533
   PubMed Web of Science ®Google Scholar
• CannonPKeagDRadfordRAtaullahSLeatherbarrowBOur experience using primary oral antibiotics in the management of orbital cellulitis in a tertiary referral centreEye200923361261518309335
   PubMed Web of Science ®Google Scholar
• DasJDekaAKuriGBhattacharjeeKDasDGogoiKBacteriology of chronic dacryocystitis in adult population of northeast IndiaOrbit200827424324718716961
   PubMedGoogle Scholar
• KubalAGaribaldiDDacryoadenitis caused by methicillin-resistant Staphylococcus aureusOphthal Plast Reconstr Surg20082415061
   PubMed Web of Science ®Google Scholar
• BriscoeDRubowitzAAssiaEChanging bacterial isolates and antibiotic sensitivities of purulent dacryocystitisOrbit2005242959816191795
   PubMedGoogle Scholar
• HarbarthSSamoreMHAntimicrobial resistance determinants and future controlEmerg Infect Dis200511679480115963271
   PubMed Web of Science ®Google Scholar
• GumsJGBoatwrightDWTottiNMartinezMAntimicrobial resistance in 11 hospitals in Puerto Rico: results of an antimicrobial resistance management (ARM) programP R Health Sci J200726318118918035809
   PubMedGoogle Scholar
• GoldsteinMHKowalskiRPGordonYJEmerging fluoroquinolone resistance in bacterial keratitis: a 5-year reviewOphthalmology199910671313131810406613
   PubMed Web of Science ®Google Scholar
• MilianiKL’HeriteauFAlfandariSSpecific control measures for antibiotic prescription are related to lower consumption in hospitals: results from a French multicentre pilot studyJ Antimicrob Chemother200862482382918658196
   PubMed Web of Science ®Google Scholar
• HobanDFelminghamDThe PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infectionsJ Antimicrob Chemother200250Suppl S1495912239228
   PubMed Web of Science ®Google Scholar
• KirbyJTMutnickAHJonesRNBiedenbachDJPfallerMAGeographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000)Diagn Microbiol Infect Dis200243430330912151191
   PubMed Web of Science ®Google Scholar
• TenoverFCMechanisms of antimicrobial resistance in bacteriaAm J Med20061196 Suppl 1S3S10; discussion S62–S70.16735149
   PubMed Web of Science ®Google Scholar
• BarlowGNathwaniDIs antibiotic resistance a problem? A practical guide for hospital cliniciansPostgrad Med J20058196168069216272230
   PubMed Web of Science ®Google Scholar
• CroftACD’AntoniAVTerzulliSLUpdate on the antibacterial resistance crisisMed Sci Monit2007136RA103RA11817534243
   PubMed Web of Science ®Google Scholar
• BrownSDRybakMJAntimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PROTEKT US studyJ Antimicrob Chemother200454Suppl 1i7i1515265831
   PubMed Web of Science ®Google Scholar
• JacobsMRFelminghamDAppelbaumPCGrunebergRNThe Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agentsJ Antimicrob Chemother200352222924612865398
   PubMed Web of Science ®Google Scholar
• MarangonFBMillerDMuallemMSRomanoACAlfonsoECCiprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitisAm J Ophthalmol2004137345345815013867
   PubMed Web of Science ®Google Scholar
• BlomquistPHMethicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis)Trans Am Ophthalmol Soc200610432234517471350
   PubMedGoogle Scholar
• McDonaldMBBlondeauJMDeCoryHHMultidrug-resistant strains in clinical trials of besifloxacin in the treatment of bacterial conjunctivitisPresented at the American Academy of Ophthalmology Annual Meeting2008 Nov 8–11Atlanta, GA, USAPoster 070.
   Google Scholar
• BuznachNDaganRGreenbergDClinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance eraPediatr Infect Dis J200524982382816148850
   PubMed Web of Science ®Google Scholar
• OhnsmanCRitterbandDO’BrienTGirgisDKabatAComparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitisCurr Med Res Opin20072392241224917688706
   PubMed Web of Science ®Google Scholar
• LichtensteinSJWagnerRSJamisonTBellBStromanDWSpeed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studiesAdv Ther20072451098111118029337
   PubMed Web of Science ®Google Scholar
• ChalitaMRHofling-LimaALParanhosAJrSchorPBelfortRJrShifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 yearsAm J Ophthalmol20041371435114700643
   PubMed Web of Science ®Google Scholar
• OliveiraADD’AzevedoPAFranciscoWIn vitro activity of fluoroquinolones against ocular bacterial isolates in Sao Paulo, BrazilCornea200726219419817251812
   PubMed Web of Science ®Google Scholar
• AfshariNAMaJJDuncanSMTrends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitisJ Ocul Pharmacol Ther200824221722318331204
   PubMed Web of Science ®Google Scholar
• TuftSJMathesonMIn vitro antibiotic resistance in bacterial keratitis in LondonBr J Ophthalmol200084768769110873974
   PubMed Web of Science ®Google Scholar
• ParmarPSalmanAKalavathyCMComparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitisAm J Ophthalmol2006141228228616458681
   PubMed Web of Science ®Google Scholar
• WilhelmusKRAbshireRLSchlechBAInfluence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitisArch Ophthalmol200312191229123312963604
   PubMedGoogle Scholar
• MoshirfarMMirzaianGFeizVKangPCFourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgeryJ Cataract Refract Surg200632351551816631067
   PubMed Web of Science ®Google Scholar
• MillerDFlynnPMScottIUAlfonsoECFlynnHWJrIn vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolatesArch Ophthalmol2006124447948316606872
   PubMedGoogle Scholar
• AsbellPASahmDFLongitudinal nationwide antimicrobial susceptibility surveillance in ocular isolates: results from Ocular TRUST 2Presented at: American Society of Cataract and Refractive Surgery Annual Meeting2007 April 27–May 2San Diego, CA, USA
   Google Scholar
• MorrisseyIBurnettRViljoenLRobbinsMSurveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002J Infect200449210911415236917
   PubMed Web of Science ®Google Scholar
• BrownLResistance to ocular antibiotics: an overviewClin Exp Optom200790425826217535364
   PubMed Web of Science ®Google Scholar
• TzepiIVergadosIKanellakopoulouKPharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental studyInt J Antimicrob Agents200933216016218947985
   PubMed Web of Science ®Google Scholar
• WiseRAndrewsJThe bactericidal activity of gatifloxacin in plasma and urineClin Microbiol Infect19984739239611864354
   PubMedGoogle Scholar
• DrusanoGLPharmacokinetics and pharmacodynamics of antimicrobialsClin Infect Dis200745Suppl 1S89S9517582578
   PubMed Web of Science ®Google Scholar
• AmbrosePGBhavnaniSMRubinoCMPharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymoreClin Infect Dis2007441798617143821
   PubMed Web of Science ®Google Scholar
• WrightDHBrownGHPetersonMLRotschaferJCApplication of fluoroquinolone pharmacodynamicsJ Antimicrob Chemother200046566968311062185
   PubMed Web of Science ®Google Scholar
• FirsovAALubenkoIYVostrovSNPortnoyYAZinnerSHAntistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolonesAntimicrob Agents Chemother20054972642264715980331
   PubMed Web of Science ®Google Scholar
• BlondeauJMZhaoXHansenGDrlicaKMutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniaeAntimicrob Agents Chemother200145243343811158737
   PubMed Web of Science ®Google Scholar
• MetzlerKHansenGMHedlinPHardingEDrlicaKBlondeauJMComparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureusInt J Antimicrob Agents200424216116715288315
   PubMed Web of Science ®Google Scholar
• DrusanoGLLouieADezielMGumboTThe crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulationsClin Infect Dis200642452553216421797
   PubMed Web of Science ®Google Scholar
• TamVHLouieAFritscheTRImpact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobialJ Infect Dis2007195121818182717492598
   PubMed Web of Science ®Google Scholar
• RobertsonSMCurtisMASchlechBAOcular pharmacokinetics of moxifloxacin after topical treatment of animals and humansSurv Ophthalmol200550Suppl 1S32S4516257309
   PubMed Web of Science ®Google Scholar
• Quixin [package insert]Jacksonville, FLVistakon Pharmaceuticals LLC42006
   Google Scholar
• BlondeauJMFluoroquinolones: mechanism of action, classification, and development of resistanceSurv Ophthalmol200449Suppl 2S73S7815028482
   PubMed Web of Science ®Google Scholar
• WardKWLepageJFDriotJYNonclinical pharmacodynamics, phar-macokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic useJ Ocul Pharmacol Ther200723324325617593008
   PubMed Web of Science ®Google Scholar
• CambauEMatratSPanXSTarget specificity of the fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coliJ Antimicrob Chemother200963344345019147516
   PubMed Web of Science ®Google Scholar
• BrunnerLSNortonSEBlondeauJMIn vitro activity of SS734, a novel fluoroquinolone, against pathogens associated with bacterial conjunctivitis[poster] 17th European Congress of Clinical Microbiology and Infectious DiseasesMarch 31–April 3, 2007Munich, GermanyPoster P1679.
   Google Scholar
• ProkschJWDriotJYWardKWNonclinical ocular and systemic pharmacokinetics of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic usePresented at the Association for Research in Vision and Ophthalmology Annual Meeting2007 Apr 27–May 1Fort Lauderdale, FL, USAPoster #B654.
   Google Scholar
• ChappaAKProkschJWWardKWComparison of the ocular and systemic pharmacokinetics of besifloxacin, a novel fluoroquinolone antibiotic, with moxifloxacin and gatifloxacin in pigmented rabbitsPresented at the Association for Research in Vision and Ophthalmology Annual Meeting2008 Apr 27–May 1Fort Lauderdale, FL, USAPoster #D684.
   Google Scholar
• ZhangJZCavetMEWardKWAnti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cellsCurr Eye Res2008331192393319085374
   PubMed Web of Science ®Google Scholar
• ZhangJZWardKWBesifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytesJ Antimicrob Chemother200861111111617965029
   PubMed Web of Science ®Google Scholar
• GranvilCPSiou-MermetRComstockTJonasseMProkschJWOcular pharmacokinetics of besifloxacin, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use, in healthy volunteersPresented at the Association for Research in Vision and Ophthalmology Annual Meeting2008 Apr 27–May 1Fort Lauderdale, FL, USAPoster #D691.
   Google Scholar
• ProkschJGranvilCPSiou-MermetRComstockTPaternoMWardKWOcular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humansJ Ocul Pharm Ther2009254335341
   Web of Science ®Google Scholar
• LiuZLiJNieSLiuHDingPPanWStudy of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacinInt J Pharm20063151–2121716616442
   PubMed Web of Science ®Google Scholar
• MansourMMansourSMortadaNDAbd ElhadySSOcular poloxamer-based ciprofloxacin hydrochloride in situ forming gelsDrug Dev Ind Pharm200834774475218612913
   PubMed Web of Science ®Google Scholar
• AbrahamSFurtadoSBharathSBasavarajBVDeveswaranRMadhavanVSustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling systemPak J Pharm Sci200922217517919339228
   PubMed Web of Science ®Google Scholar
• KarpeckiPDePaolisMHunterJABesifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyClin Ther200931351452619393842
   PubMed Web of Science ®Google Scholar
• TepedinoMEHellerWHUsnerDWPhase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisCurr Med Res Opin20092551159116919323612
   PubMed Web of Science ®Google Scholar
• McDonaldMBProtzkoEEBrunnerLSEfficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitisOphthalmology200911691615162319643483
   PubMed Web of Science ®Google Scholar
• Antibiotic/Antimicrobial Resistance: Clinical guidelinesAvailable at: http://www.cdc.gov/DRUGRESISTANCE/clinical.htm Accessed Dec. 5, 2008.
   Google Scholar
• World Health Organization Antimicrobial resistance. Available at: http://www.who.int/mediacentre/factsheets/fs194/en/print.html 2002 Fact sheet 194 Accessed Dec. 5, 2008.
   Google Scholar
• YoneyamaHKatsumataRAntibiotic resistance in bacteria and its future for novel antibiotic developmentBiosci Biotechnol Biochem20067051060107516717405
   PubMed Web of Science ®Google Scholar